Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
ROCKET PHARMACEUTICALS, INC. reported that officer John Militello participated in an option exchange program on May 26, 2026. The company cancelled multiple out-of-the-money stock options previously held by him and took them back as a disposition to the issuer.
In exchange, Militello received several new stock options to buy common stock at an exercise price of $3.00 per share, which footnotes state was the closing price of the common stock on that date. The new grants cover different amounts and maturities, including rights to purchase 9,091 shares expiring on February 16, 2034 and 51,509 shares expiring on May 26, 2031, all subject to continued employment-based vesting.
The cancelled options included higher-strike awards such as 24,545 options at an exercise price of $30.01 and 49,798 options at $20.04, among other tranches with exercise prices up to $62.32 per share.
ROCKET PHARMACEUTICALS, INC. reported that officer John Militello participated in an option exchange program on May 26, 2026. The company cancelled multiple out-of-the-money stock options previously held by him and took them back as a disposition to the issuer.
In exchange, Militello received several new stock options to buy common stock at an exercise price of $3.00 per share, which footnotes state was the closing price of the common stock on that date. The new grants cover different amounts and maturities, including rights to purchase 9,091 shares expiring on February 16, 2034 and 51,509 shares expiring on May 26, 2031, all subject to continued employment-based vesting.
The cancelled options included higher-strike awards such as 24,545 options at an exercise price of $30.01 and 49,798 options at $20.04, among other tranches with exercise prices up to $62.32 per share.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported an option exercise and related share sale in Common Stock. He exercised stock options for 76,490 shares at $1.691 per share and sold 55,684 shares at a weighted average price of $3.086 per share.
According to the disclosure, the sale was made to pay the option exercise price and cover certain taxes tied to the exercise. After these transactions, Shah directly holds 1,061,724 shares of Common Stock, and additional shares are held indirectly through a trust and by his spouse. Direct holdings include Restricted Stock Units that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported an option exercise and related share sale in Common Stock. He exercised stock options for 76,490 shares at $1.691 per share and sold 55,684 shares at a weighted average price of $3.086 per share.
According to the disclosure, the sale was made to pay the option exercise price and cover certain taxes tied to the exercise. After these transactions, Shah directly holds 1,061,724 shares of Common Stock, and additional shares are held indirectly through a trust and by his spouse. Direct holdings include Restricted Stock Units that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small share sale primarily tied to equity compensation. On common stock, he sold 2,409 shares in an open-market transaction at about $3.014 per share to pay tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
After this transaction, Shah directly holds 1,040,918 shares of common stock, and also reports indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that his holdings include RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small share sale primarily tied to equity compensation. On common stock, he sold 2,409 shares in an open-market transaction at about $3.014 per share to pay tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
After this transaction, Shah directly holds 1,040,918 shares of common stock, and also reports indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that his holdings include RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported a small open-market sale of company common stock. He sold 662 shares on May 19, 2026 at an average price of $3.014 per share. Footnotes state the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units that convert into common stock on a one-for-one basis. After this transaction, he continues to hold 677,977 shares of common stock, indicating the sale represents a very small portion of his overall position.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported a small open-market sale of company common stock. He sold 662 shares on May 19, 2026 at an average price of $3.014 per share. Footnotes state the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units that convert into common stock on a one-for-one basis. After this transaction, he continues to hold 677,977 shares of common stock, indicating the sale represents a very small portion of his overall position.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported selling 384 shares of common stock at $3.014 per share on May 19, 2026. According to the footnotes, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this transaction, Militello directly holds 89,780 shares of common stock. The filing characterizes the trade as an open-market sale but clarifies that its purpose was to cover taxes related to equity compensation rather than a discretionary portfolio adjustment.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported selling 384 shares of common stock at $3.014 per share on May 19, 2026. According to the footnotes, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this transaction, Militello directly holds 89,780 shares of common stock. The filing characterizes the trade as an open-market sale but clarifies that its purpose was to cover taxes related to equity compensation rather than a discretionary portfolio adjustment.
Rocket Pharmaceuticals files a Form 144 to sell 55,684 shares. The filing lists an intended sale of 55,684 shares of Common Stock via an option granted on 04/12/2017, with the sale dated 05/21/2026 for cash. The filing also discloses recent transfers: 2,728 shares sold on 05/13/2026 for $9,836.08 and 2,409 shares sold on 05/19/2026 for $7,261.69.
Rocket Pharmaceuticals files a Form 144 to sell 55,684 shares. The filing lists an intended sale of 55,684 shares of Common Stock via an option granted on 04/12/2017, with the sale dated 05/21/2026 for cash. The filing also discloses recent transfers: 2,728 shares sold on 05/13/2026 for $9,836.08 and 2,409 shares sold on 05/19/2026 for $7,261.69.
Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Form 144 notice reporting a proposed sale of 2,409 Common shares associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also discloses 2,728 Common shares sold during the prior three months on 05/13/2026.
Form 144 notice reporting a proposed sale of 2,409 Common shares associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also discloses 2,728 Common shares sold during the prior three months on 05/13/2026.
RCKT filing a Form 144 notice reporting the sale or proposed sale of 384 shares of common stock associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also lists a prior sale of 855 shares on 05/13/2026.
RCKT filing a Form 144 notice reporting the sale or proposed sale of 384 shares of common stock associated with a Restricted Stock Vesting event dated 05/15/2026. The filing also lists a prior sale of 855 shares on 05/13/2026.
RCKT submitted a Rule 144 notice covering 662 shares of Common Stock.
The filing states the 662 shares arose from Restricted Stock Vesting dated 05/15/2026. It also records a separate sale of 3,361 shares on 05/13/2026 with proceeds of $12,118.42.
RCKT submitted a Rule 144 notice covering 662 shares of Common Stock.
The filing states the 662 shares arose from Restricted Stock Vesting dated 05/15/2026. It also records a separate sale of 3,361 shares on 05/13/2026 with proceeds of $12,118.42.